Cargando…

Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer

Metastatic castrate-resistant prostate cancer remains a disease hard to cure, and for this reason predictive tools to monitor disease progression and therapy response are an urgent need. In this respect, liquid biopsy on circulating cell-free nucleic acids represents an interesting strategy based on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sobhani, Navid, Sirico, Marianna, Generali, Daniele, Zanconati, Fabrizio, Scaggiante, Bruna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7407926/ https://www.ncbi.nlm.nih.gov/pubmed/32821651 http://dx.doi.org/10.5306/wjco.v11.i7.450

Ejemplares similares

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

An Overview of Circulating Cell-Free Nucleic Acids in Diagnosis and Prognosis of Triple-Negative Breast Cancer
por: Tierno, Domenico, et al.
Publicado: (2023)

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma
por: Sobhani, Navid, et al.
Publicado: (2017)

A Case–Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection
por: Bortul, Marina, et al.
Publicado: (2023)

Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications
por: Tierno, Domenico, et al.
Publicado: (2023)

Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
por: Bosutti, Alessandra, et al.
Publicado: (2016)

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption
por: Sobhani, Navid, et al.
Publicado: (2021)

The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
por: Roviello, Giandomenico, et al.
Publicado: (2019)

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2018)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study
por: Alborelli, Ilaria, et al.
Publicado: (2019)

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy
por: Sobhani, Navid, et al.
Publicado: (2017)

Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma
por: D’Angelo, Alberto, et al.
Publicado: (2019)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

Role of the IGF-1 Axis in Overcoming Resistance in Breast Cancer
por: Ianza, Anna, et al.
Publicado: (2021)

Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer
por: Lin, Hui-Ming, et al.
Publicado: (2021)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer
por: Hamano, Itsuto, et al.
Publicado: (2020)

Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
por: Giudici, Fabiola, et al.
Publicado: (2019)

Correction: Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis
por: Giudici, Fabiola, et al.
Publicado: (2019)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Characterizing Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles in Metastatic Castration-Naive and Castration-Resistant Prostate Cancer Patients
por: Isebia, Khrystany T., et al.
Publicado: (2022)

A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens
por: Jimenez, Rafael E., et al.
Publicado: (2019)

High eEF1A1 Protein Levels Mark Aggressive Prostate Cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1–actin Complex as a New Potential Target for Therapy
por: Bosutti, Alessandra, et al.
Publicado: (2022)

Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Wang, Chun, et al.
Publicado: (2021)

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
por: Magbanua, Mark Jesus M, et al.
Publicado: (2012)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience
por: Ianza, Anna, et al.
Publicado: (2021)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
por: Sobhani, Navid, et al.
Publicado: (2021)

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer
por: Garje, Rohan, et al.
Publicado: (2019)

Epigenetic markers in circulating cell‐free DNA as prognostic markers for survival of castration‐resistant prostate cancer patients
por: Hendriks, Rianne J., et al.
Publicado: (2018)

Presence of CD133‐positive circulating tumor cells predicts worse progression‐free survival in patients with metastatic castration‐sensitive prostate cancer
por: Yang, Yunjie, et al.
Publicado: (2022)

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel
por: de Kruijff, Ingeborg E., et al.
Publicado: (2019)

Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer
por: Gerdtsson, Anna S., et al.
Publicado: (2021)

Association of Circulating Tumor Cells with Inflammatory and Biomarkers in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer
por: Theil, Gerit, et al.
Publicado: (2021)

Analysis of Circulating Immune Biomarkers by Race in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Sipuleucel-T
por: Hawley, Jessica E, et al.
Publicado: (2021)

Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Groen, Levi, et al.
Publicado: (2023)

Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer
por: Gourdin, Theodore, et al.
Publicado: (2018)

Impact of psychosocial, behavioral and lifestyle factors on subjective cognitive complaints and perceived quality of life in a large cohort of Italian breast cancer patients
por: West, Thomas, et al.
Publicado: (2022)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tr11s944hou8udhn9k1l0dnc3b